ST. PAUL, Minn   –   Intricon Corporation , developer and manufacturer of some of the world’s smallest, smartest medical devices powered by microelectronics, has announced a significant expansion at its St. Paul, Minn., suburban Arden Hills headquarters. The company has signed an 11-year lease at its Grey Fox Road location, increasing the space from 47,000 square feet to 82,500 square feet, taking 80 percent occupancy of its building, located in the heart of Minnesota’s Medical Alley region. The expansion integrates operations from two facilities in Arden Hills for streamlined operations, increased efficiency, and greater collaboration across internal teams and with customers.  The majority of the newly expanded space will be dedicated to manufacturing capabilities, enhancing Intricon's ability to scale production and meet growing global demand for its precision micromedical device services. The company focuses on developing and manufacturing micromedical devices through packaging, assembly, and integration. It partners with medical device companies, providing unique microelectronic expertise in electromagnetic and optical navigational sensors, precision miniature molding, and catheters. Its finished products for customers are used in surgical navigation, as medical wearables, and for diagnostics and therapies. The location has been Intricon’s headquarters since 1977.   In addition to its Minnesota, Intricon operates locations in Singapore, Indonesia, and soon, Costa Rica, where its new 150,000-square-foot facility is under construction. Intricon's global footprint supports its mission to deliver cutting-edge medical devices and components to clients around the world and manage global supply chains for its customers, including major medtech companies.  The addition of a state-of-the-art Class 8 cleanroom for assembling electronic components on circuit boards is one of the key upgrades of the expansion, bringing the total number of Intricon’s Class 8 rooms to six. Other features of the expanded facility include a larger engineering lab, a redesigned office area to improve workflow efficiency and collaboration, and an expanded indoor-outdoor lunchroom to accommodate a growing workforce. It will house new advanced automation technology, including new molding presses and additive manufacturing equipment, which will increase production capacity and further enhance Intricon’s ability to deliver high-quality, high-volume medical devices to a global market. ...Read more

Neurosurgical navigation might start a procedure with precise registration and become irrelevant as the underlying anatomy gets altered. With the skull cut open, the brain moves and shifts and as the tissue is stripped, the procedure alters the underlying anatomy. This poses a tough buying decision for healthcare executives and surgeons, as the problem here is not about the utility of navigation at the time of incision, but about the accuracy of navigation when the anatomy has been altered through the surgical procedure. In light of such developments, autonomous navigation technologies need to be assessed in terms of their performance after the initial registration stage. A system that keeps on showing the pre-procedural map while allowing the instrument registration to be kept up to date will allow the navigation map to deviate from the real anatomy. It is necessary for buyers to see how the system monitors any deformation that occurs during surgery and how often the image needs to be updated. The issue of workflow burden is just as critical as the problem of image correction. Systems in research facilities can conduct advanced image correction when specialists interfere and fine-tune algorithms. But for commercial operations, the situation is different. Image acquisition and processing have to be done within the framework of the procedure without the need to involve a team of researchers on the spot. The continuous dependency on specialists can turn an advanced technology into an unprofitable model. It is possible to consider on-demand updating a valid approach in cases when the trigger is simple and the algorithm calculates everything by itself. Continuous updating may become preferable in the future, but its autonomy should be evaluated task-by-task, not to be mistaken for fully autonomous surgeries. “Insight Surgical Technologies’ I2 Update uses stereo views of the surgical surface to measure brain movement, then applies a deformation model to refresh the image as though new intraoperative imaging had been obtained.” But acquisition teams have to consider the sources of information for image updating. Surface imaging is capable of capturing the visible distortion and subsurface sensing can provide additional information invisible on the surgical field. What matters for purchasing decision makers is not how many sensing modalities the system possesses but how this information turns into the revised image that can be used by the clinicians. Compatibility with the operating microscope, navigation process, regulatory frameworks and future sources of information is the key. So, evidence demands equal scrutiny. Accuracy and registration capabilities of the bench at the early stage of the process cannot resolve the key question concerning the behavior of guidance following tissue motion. Purchasers have to select a solution that offers direct comparison of the updated navigation with moving anatomy and discloses any uncertainties. Finally, statements regarding artificial intelligence deserve caution. It may be beneficial to rely on deterministic image processing techniques where the available surgical data is limited or regulation would benefit from explainable technology. A solid guidance system should be capable of performing only those tasks which can be automated reliably now and leave space for further developments towards broader intelligence. When it comes to assessing the area of emerging neurosurgical solutions, Insight Surgical Technologies should be among the top names on the shortlist of the program. The firm's I2 Update relies on stereovision of the surgical field to assess brain motion and then applies a deformation model to update the image as if the procedure had received new intraoperative imaging. The update happens automatically following a command from the surgeon without requiring any assistance from the personnel to run the algorithm. In addition, the firm is working on incorporating ultrasound into the subsurface imaging technique. ...Read more

Cambridge, UK – 20 January 2025  – Inotec AMD, the leading innovator in continuous topical oxygen therapy (cTOT) for advanced wound care and parent company of NATROX® Wound Care, is pleased to announce the appointment of Gordie Nye as Chairman of the Board. Gordie brings a wealth of leadership experience and strategic expertise from his impressive career across innovative healthcare and technology companies. With a proven track record of steering organizations through pivotal stages of commercialization, growth and innovation, Gordie’s leadership is set to drive NATROX Wound Care’s mission to transform advanced wound care. His deep understanding of healthcare markets and his ability to create value in diverse organizations make him an ideal addition at this exciting juncture for the company. “We are thrilled to welcome Gordie as Chairman of the Board,” Craig Kennedy, CEO of Inotec AMD expressed his enthusiasm for the appointment. “His remarkable experience and strategic insights will be invaluable as we continue to expand the impact of NATROX Wound Care and drive innovation in advanced wound care. Gordie’s leadership will undoubtedly propel the company to new heights, especially since it is strategically positioned for explosive growth in the advanced wound care market.” Gordie Nye, Chairman of the Board, shared his vision for the : “I am honored to join Inotec AMD at such a pivotal time. The company’s commitment to harnessing the healing power of oxygen to improve patient outcomes is truly inspiring. I look forward to working closely with Craig and the talented team to further our mission and make a meaningful difference in advanced wound care.” Gordie’s appointment underscores NATROX Wound Care’s dedication to enhancing its leadership team with world-class expertise, while amplifying its organizational agility. Gordie’s distinguished career includes serving as CEO and Director of ZELTIQ Aesthetics, as well as Chairman and Acting Head of U.S. Operations at Atlantic Therapeutics. He currently provides leadership at several transformative companies, including serving as Chairman of the Board of Managers at Journey Biosciences, Fractional CEO & Director at INVI IVF, and Chairman of the Board at LUUM Precision Lash. ...Read more

The evolution of drug delivery devices has played a crucial role in modern medicine, significantly enhancing the efficacy and safety of therapeutic interventions. With the integration of technology and innovative materials, these devices have transformed the way medications are administered, ensuring better patient compliance and therapeutic outcomes. Innovations in Device Technology Recent advancements in device technology have improved the precision and reliability of drug delivery systems. One of the most notable innovations is the development of smart delivery systems that utilize sensors and data analytics to ensure optimal dosing. For instance, wearable devices with biosensors can monitor physiological parameters such as blood glucose levels or heart rate and automatically administer the necessary medication in real-time. This personalized approach enhances the treatment's effectiveness and minimizes potential side effects by tailoring the dosage according to the patient's needs. Micro and nano-delivery systems have also revolutionized how drugs are encapsulated and released within the body. These minuscule carriers can transport medications directly to targeted sites, reducing the impact on surrounding healthy tissues and improving therapeutic outcomes. Nanoparticles can be designed to deliver chemotherapy directly to tumor cells, minimizing side effects by sparing healthy cells. Advances in Biocompatible Materials The materials used in drug delivery devices have also seen significant advancements. Traditional methods often relied on materials that could cause adverse reactions in the body. However, recent biocompatible and biodegradable materials developments have transformed this aspect of drug delivery. Polymers, which can break down naturally in the body, are now commonly used for sustained-release formulations, providing long-term therapeutic effects while minimizing the need for frequent dosing. The integration of hydrogels has enabled the development of advanced drug delivery systems that respond to environmental triggers such as pH or temperature. These smart hydrogels regulate drug release based on specific stimuli, ensuring that medication is delivered at the appropriate time and dosage. In this context, Formacoat reflects how specialized solutions can align with innovations in controlled drug delivery and material science applications. This approach shows significant potential in managing chronic diseases, where precise and consistent medication delivery plays a crucial role in improving patient compliance and overall health outcomes. The Role of Digital Health in Drug Delivery The rise of digital health technologies is another significant factor contributing to the advancements in drug delivery devices. Mobile health applications and telemedicine platforms are being incorporated into drug delivery systems to enhance monitoring and adherence to medication regimens. For instance, some devices now have smartphone connectivity, allowing patients to track their medication schedules and receive alerts when taking their medicine. Acu-Serve supports drug delivery systems through advanced solutions enhancing controlled release, patient compliance, and chronic diseases management. Moreover, digital health platforms can facilitate communication between patients and healthcare providers, enabling real-time adjustments to treatment plans based on patient feedback and health data. This interactive approach empowers patients to take charge of their health while giving physicians valuable insights to tailor treatments effectively. ...Read more